

WEBINAR
ARON RESEARCH FOUNDATION
“My point of view on Genitourinary Oncology”

25 novembre 2026
FILE UNICO

TITOLO	<i>My point of view on Genitourinary Oncology</i>
DATA	25/11/2026
EVENTO ECM	ID 3282 – 497716
CREDITI ECM	3,00
SEDE	Online
PROVIDER ECM	ALFA FCM Srl / Sede operativa: Via Barnaba Oriani, 114 – 00197 Roma. Sede legale: Viale Mazzini, 6 - 00195 Roma / C.F. e P.IVA 11408311006
SEGRETERIA ORGANIZZATIVA	ACCURATE S.r.l., Sede Legale: 43122 Parma (PR) (I), via Alfredo Veroni 37a Sede Operativa: 47522 Cesena (FC) (I), via Anna Kuliscioff 230. Tel. 0547/20630
OGGETTO DELLA TEMATICA	Renal cell carcinoma (RCC), urothelial carcinoma (UC), and advanced prostate cancer (mHSPC/mCRPC).
RESPONSABILE SCIENTIFICO	Matteo Santoni, Dirigente Medico Oncologia AST Macerata

DESTINARI Medico Chirurgo
(Oncologia, Chirurgia generale, Ginecologia e ostetricia, Anatomia patologica, Biochimica clinica, Radiodiagnostica)

RAZIONALE

ARON Research Foundation ETS is a global non-profit dedicated to advancing research in genitourinary oncology. We bridge the gap between scientific discovery and clinical practice by fostering specialized education for healthcare professionals and championing equitable access to treatment through global healthcare reporting.

This webinar will focus on the latest, practice-changing updates in the management of renal cell carcinoma (RCC), urothelial carcinoma (UC), and advanced prostate cancer (mHSPC/mCRPC). Leading international experts will share their unique perspectives on emerging therapeutic strategies, including modern adjuvant and perioperative approaches, PARP inhibitors, antibody-drug conjugates (ADCs), and mechanisms to overcome immunotherapy resistance. By exploring these cutting-edge advancements, the event aims to translate recent clinical trial data into optimized, real-world patient care.

PROGRAMMA

25 novembre 2026

14.30 Presentation of the meeting – Matteo Santoni

My point of view on...

- 14.40 "Adjuvant therapies for RCC and UC" – Fernando Sabino Marques Monteiro (BRA)
- 15.00 "Achieving and managing complete remissions in RCC" – Maite Bourlon (MEX)
- 15.20 "Intensification and De-Intensification in mHSPC" – Pasquale Rescigno (UK)
- 15.40 "Best setting for PARP inhibitors in mHSPC and mCRPC" – Andrey Soares (BRA)
- 16.00 "Primary refractory to immunotherapy and to ADC in RCC and UC" – Matteo Santoni (ITA)
- 16.20 "Perioperative and adjuvant approaches in UC" – Javier Molina-Cerrillo (SPN)
- 16.40 Take home messages

ACRONIMI

RCC: renal cell carcinoma,
UC: urothelial carcinoma (UC),
mHSPC/mCRPC: advanced prostate cancer

